Spartalizumab
- Generic Name
- Spartalizumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1935694-88-4
- Unique Ingredient Identifier
- QOG25L6Z8Z
- Background
Spartalizumab is under investigation in clinical trial NCT02605967 (Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma).
- Associated Conditions
- -
- Associated Therapies
- -
Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies
- First Posted Date
- 2019-06-27
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 122
- Registration Number
- NCT04000529
- Locations
- ๐บ๐ธ
Massachusetts General Hospital, Boston, Massachusetts, United States
๐ช๐ธNovartis Investigative Site, Valencia, Comunidad Valenciana, Spain
Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-08-27
- Last Posted Date
- 2022-01-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 18
- Registration Number
- NCT03647488
- Locations
- ๐บ๐ธ
Highlands Oncology Group, Fayetteville, Arkansas, United States
๐ช๐ธNovartis Investigative Site, Madrid, Spain
A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma
- Conditions
- Interventions
- First Posted Date
- 2016-11-18
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 573
- Registration Number
- NCT02967692
- Locations
- ๐บ๐ธ
California Cancer Associates for Research and Excellence, Encinitas, California, United States
๐บ๐ธUC Irvine Medical Center, Orange, California, United States
๐บ๐ธStanford Cancer Center, Stanford, California, United States
Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC
- Conditions
- Interventions
- First Posted Date
- 2016-06-10
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 89
- Registration Number
- NCT02795429
- Locations
- ๐จ๐ณ
Novartis Investigative Site, Taipei, Taiwan
Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2015-11-17
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 122
- Registration Number
- NCT02605967
- Locations
- ๐น๐ญ
Novartis Investigative Site, Chiang Mai, Thailand
๐บ๐ธKarmanos Cancer Institute, Detroit, Michigan, United States
๐บ๐ธNorthwest Georgia Oncology Center NWGA Onc - Carrollton, Marietta, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.